An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Phase 3
Completed
- Conditions
- Juvenile Psoriatic ArthritisEnthesitis Related Arthritis
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT03769168
- Locations
- πΊπΈ
St Lukes Intermountain Research Center, Boise, Idaho, United States
πΊπΈCincinnati Childrens Hospital, Cincinnati, Ohio, United States
πΊπΈLegacy Emanuel Research Hospital Portland, Portland, Oregon, United States
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Phase 2
Completed
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03765788
- Locations
- π©πͺ
Novartis Investigative Site, Wuerzburg, Germany
HDM201 Added to CT in R/R or Newly Diagnosed AML
Phase 1
Withdrawn
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Drug: anthracyclineDrug: liposomal cytarabine/daunorubicin
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03760445
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
Phase 2
Completed
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT03756129
- Locations
- πͺπΈ
Novartis Investigative Site, Barcelona, Spain
Study of Efficacy of PEAR-004 in Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Device: PEAR-004Device: Sham
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03751280
- Locations
- πΊπΈ
Novartis Investigative Site, Albuquerque, New Mexico, United States
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Phase 1
Terminated
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT03742349
- Locations
- πΊπΈ
Columbia University Medical Center- New York Presbyterian Columbia, New York, New York, United States
πͺπΈNovartis Investigative Site, Valencia, Comunidad Valenciana, Spain
πΊπΈSarah Cannon Research Institute Sarah Cannon Research, Nashville, Tennessee, United States
MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03720626
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03718533
- Locations
- πͺπΈ
Novartis Investigative Site, Barcelona, Spain
This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT03713619
- Locations
- π¬π§
Novartis Investigative Site, Norwich, United Kingdom
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT03713632
- Locations
- π»π³
Novartis Investigative Site, Ho Chi Minh, Vietnam
Β© Copyright 2025. All Rights Reserved by MedPath